Drug intelligence / Profile preview

IFB03

Development stage: Preclinical
Lead developer: Interface Biosciences
Modality: Modified Peptides → Peptides

Overview

IFB03 is a discovery-stage therapeutic candidate being developed by Interface Biosciences for the treatment of wound healing. It is a sactipeptide (sulfur-alpha-carbon thioether peptide), a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) characterized by thioether bridges that provide enhanced stability and unique structural properties. IFB03 is designed to target and modulate Interleukin-6 (IL-6) signaling, a critical pathway involved in the inflammatory response and tissue regeneration. By regulating IL-6 activity, IFB03 aims to optimize the wound healing process and potentially address complications associated with chronic wounds or pathological scarring.

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on IFB03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFB03.

Explore the full profile